

Notice of 340B Price Calculation for Locametz and Netspot

September 18, 2023

At the direction of the Centers for Medicare & Medicaid Services (CMS), Advanced Accelerator Applications USA (“ADACAP”), a Novartis Company (Novartis) is treating its two diagnostic radiopharmaceuticals as covered outpatient drugs:

- Netspot Kit (69488-0001-40), supplied for the preparation of gallium Ga 68 dotatate injection, and
- Locametz Kit (69488-0017-61), supplied for the preparation of gallium Ga 68 gozetotide injection.

As such, we are now calculating and reporting pricing information for these two products under Medicaid Drug Rebate and 340B Drug Pricing Programs back to the effective date of ADACAP’s Medicaid Drug Rebate and Pharmaceutical Pricing Agreements, May 2018.

Accordingly, we will be offering refunds to Covered Entities with respect to purchases of Locametz and Netspot effective the later of May 2018 or the product’s launch date (the launch date for Netspot is July 21, 2016 and for Locametz is March 29, 2022) (the Refund-Eligible Period), and where the units qualify for the 340B ceiling price because they qualify as Covered Outpatient Drugs. A Covered Entity that meets the following criteria will be eligible for a refund:

1. Was registered as an eligible participating Covered Entity in the Office of Pharmacy Affairs Information System (OPAIS) at the time of purchase during the Refund-Eligible Period;
2. Purchased NDC 69488-0001-40 (Netspot Kit) and/or 69488-0017-61 (Locametz Kit) at a price greater than the 340B ceiling price; and
3. Can demonstrate that the unit(s) purchased qualify as a Covered Outpatient Drug.

Refund Request Process:

Novartis requests that any Covered Entity with qualifying purchases submit a refund request to Novartis at adacap.340b@novartis.com, inclusive of supporting documentation. Novartis will then work with the Covered Entity to process any refund that is due for the applicable NDC(s). Refunds will be issued in the form of a credit in an amount equal to the difference between the original purchase price, net of any applicable discounts, and the 340B ceiling price.

If you have any questions or require assistance with respect to the refund request, please contact John Runfola at (862) 529-8132 or by e-mail at john.runfola@novartis.com during regular business hours.

Novartis has asked the Office of Pharmacy Affairs (OPA) to post this Notice on OPA’s public website to facilitate giving affected covered entities the opportunity to request refunds.